 |
 |
 |
 |
 |
 |
 |
 |
E-Mail
ShareInterleukin & HIV/AIDS: Research
See also: Research on Immune-Based Therapies
Overview
- Research Shows Treating HIV/AIDS With Interleukin-2 Is Ineffective (October 23, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - A Clinical Overview of Aldesleukin (IL-2, Proleukin) (June 7, 2009)
From AIDSinfo - The Development Pipeline for Cytokines, Immunomodulators and Gene Therapy (September 29, 2005)
In TAGline, from Treatment Action Group - Interleukin-2: SILCAAT Study to Continue (October 2003)
[Archived Article]
To read PDF, click here.
In Project Inform Perspective, from Project Inform - Company Backs Out of Immune Drug Study (November 1, 2002)
[Archived Article]
From Canadian AIDS Treatment Information Exchange - IL-2: Promiscuous Cytokine or Steady Date? (Winter 2001/2002)
[Archived Article]
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America - The Role of IL-10 in Long-Term Non-Progressors (Winter 2001/2002)
[Archived Article]
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
Trial Results
- IL-2 Confers No Long-Term Benefits (Winter/Spring 2009)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - Intriguing IL2 Study Results May Offer Unique Solution (August 6, 2008)
From Project Inform - Interleukin-2 Ineffective in Maintaining Baseline CD4+ Cell Count During Treatment Interruption (February 6, 2008)
From The Body PRO - TILT: A Look at the Role of Interleukin-2 in Treatment Interruption Leans Toward the Negative (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Interleukin-2 Expands Select CD4+ T-Cell Populations, but Has No Effect on HIV-Specific Immune Responses (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Scientists Explore Possible New Way to Fight AIDS (February 8, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Comparing a Treatment Interruption With or Without Interleukin-2 in Delaying a Falling CD4+ Cell Count (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - HIV Patients Get Long-Term Boost With Short, Intermittent Drug Regimen (April 26, 2004)
From U.S. National Institute of Allergy and Infectious Diseases - Immunological and Virological Efficacy of ALVAC-VIH 1433 and HIV Lipopeptides (Lipo-6T) Combined With SC IL-2 in Chronically HIV-Infected Patients -- Results of the ANRS 093 Randomized Study (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - IL-2 & CD4 T Cells: Number & Function Disconnect? (January/February 2003)
[Archived Article]
In TAGline, from Treatment Action Group - Interleukin-2 (IL-2, Proleukin) and Immune Function (January 2003)
[Archived Article]
Research from the 2002 International AIDS Conference.
To read PDF, click here.
In Project Inform Perspective, from Project Inform - Setback for Validation of IL-2 (November 2002)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis - Baseline Characteristics Associated With CD4+ Response After Three Cycles of Subcutaneous (SC) Recombinant Human Interleukin-2 (IL-2) (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Intermittent IL-2 Administration in HIV Infected Patients Leads to a Decrease in CD4+ T Cell Turnover Rates (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Interleukin-2 Improves CD4+ Cell Counts in Patients with Poor Immune Response to HAART (April 2001)
[Archived Article]
In HIV Treatment Bulletin - Experimental Immune Modulator Drugs (Spring 2001)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - Extended Therapy with Subcutaneous Interleukin-2 (scIL-2) in HIV-Infection: Long-Term Follow-Up of 3 Trials (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Prediction of CD4+Cell Response to Subcutaneous Recombinant Interleukin-2 (SCrIL-2) (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - A Randomized Trial of Interleukin-2 (IL-2) Added to HAART for Primary HIV (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Immunomodulation of Chronic HIV-1 Infection: Impact of HAART, Interleukin-2 and/or an Inactivated gp120-Depleted HIV-1 Immunogen (REMUNE) (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Prospective, Randomized, Controlled Phase II Study of Highly Active Antiretroviral Therapy (HAART) with Continuous IV (CIV) or Subcutaneous (SC) Interleukin-2 (IL-2) in HIV-Infected Patients with CD4+Counts of 50 -- 350 cells/mm3: ACTG 328 -- Final Result (February 5, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.